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Lipopolysaccharide (LPS) is the major molecular component of the outer membrane of Gram-negative bacteria and serves as a physical barrier
providing the bacteria protection from its surroundings. LPS is also recognized by the immune system as a marker for the detection of bacterial
pathogen invasion, responsible for the development of inflammatory response, and in extreme cases to endotoxic shock. Because of these
functions, the interaction of LPS with LPS binding molecules attracts great attention. One example of such molecules are antimicrobial peptides
(AMPs). These are large repertoire of gene-encoded peptides produced by living organisms of all types, which serve as part of the innate immunity
protecting them from pathogen invasion. AMPs are known to interact with LPS with high affinities. The biophysical properties of AMPs and their
mode of interaction with LPS determine their biological function, susceptibility of bacteria to them, as well as the ability of LPS to activate the
immune system. This review will discuss recent studies on the molecular mechanisms underlying these interactions, their effects on the resistance
of the bacteria to AMPs, as well as their potential to neutralize LPS-induced endotoxic shock.
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the innate immune system
Living organisms of all types have been shown to produce a
large repertoire of gene-encoded cell-lytic peptides that serve as
part of their innate immunity to pathogen invasion [1–6]. These
lytic peptides were initially found in invertebrates [1], and were⁎ Corresponding author. Tel.: +972 8 9342711; fax: +972 8 9344112.
E-mail address: Yechiel.Shai@weizmann.ac.il (Y. Shai).
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.05.017later discovered in vertebrates, including humans [2,4,7–11].
For example, in higher organisms there are two main families of
antimicrobial peptides; defensins and cathelicidins, each
includes a group of homologues peptides [12,13]. These
peptides are mainly produced on epithelial surfaces and in
phagocytic cells, easily stored in large amounts and readily
available. As a part of the innate immune system, antimicrobial
peptides are secreted shortly after infection; they rapidly
neutralize a broad range of microbes without high specificity
or ability to induce an immunological memory. This
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and deployment of pathogen-specific immune responses occur
slowly relative to the potential kinetics of microbial prolifera-
tion. Note, that although most of the peptides show direct
antimicrobial activity in vitro [4], only some were reported to
lyse bacteria under physiological conditions [14].
Until now, more than 800 natural antimicrobial peptides have
been isolated and characterized (see a complete list at http://www.
bbcm.univ.trieste.it/∼tossi/pag1.htm) [4,15,16]. Although these
peptides differ widely in sequence and source, most of them are
composed of all L-amino acids, display a net positive charge
(ranging from+2 to+9) and share well defined α-helical or β-
strand secondary structures. Theα-helical antimicrobial peptides
are abundant in the extracellular fluids and exist as extended or
unstructured conformers in solution. Many of these peptides
become helical and form amphipatic structures upon interaction
with membranes, a structure assumed to be important for their
activities [16–21]. The mode of action of antimicrobial peptides
has been dealt within detail in many review articles, and is also
addressed in this special issue on antimicrobial peptides, and
therefore will not be discussed here. This review will discuss
studies revealing how these interactions affect the resistance of
the bacteria to antimicrobial peptides and the potential of
Lipopolysaccharide (LPS) to induce endotoxic shock.
2. Lipopolysaccharide (LPS) and its direct role in
antibacterial resistance
LPS (also termed endotoxin) is the major component of the
outer membrane of Gram-negative bacteria [22,23]. These
negatively charged molecules consist of a preserved lipophilic
component lipid A and polysaccharides, or oligosaccharides
linked to this membrane anchored domain. The saccharide
portion is diverse in length and composition amongst the dif-
ferent Gram-negative bacteria species [22]. The outer mem-
brane of Gram-negative bacteria (cell wall) is an asymmetric
membrane. LPS covers more than 90% of the cell surface in its
outer leaflet, whereas phospholipids that are located in the inner
leaflet, have a composition similar to that of the cytoplasmic
inner membrane. This unique membrane serves as a physical
barrier, providing the bacteria protection from antibacterial
agents [15,24,25]. This assumption is supported by the findings
that some antimicrobial peptides are active against one bacterial
strain but not against others, although the inner membranes of
these bacteria have similar phospholipid compositions [15].
This is because of the differences in the LPS composition of the
various strains [26]. Furthermore, different sensitivities were
found for some antibacterial peptides of deep rough bacteria,
compared to smooth phenotypes that are diverse in the length of
LPSs' saccharidic portion [27,28]. Gram-negative bacteria outer
membrane serves as the first barrier encountered by peptides
and they need to transverse it in order to reach the inner
cytoplasmic membrane. Initially, the peptides interact with the
LPS exterior and competitively displace the divalent cations
that partially neutralize the LPS negative charge [3]. Rana et al.
studied the effect of LPS structure on the interaction between
magainin 2 and Salmonella typhimurium outer membrane [29].In this study they found that the susceptibility of Gram-negative
cells to magainin 2 is associated with factors that facilitate the
transport of the peptide across the outer membrane, such as the
magnitude and location of LPS charge, the concentration of LPS
in the outer membrane, outer membrane molecular architecture,
and the presence or absence of the O-antigen side chain [29]. In
another study, Gutsmann et al. [30] investigated the mechanism
of action of the rabbit antimicrobial protein CAP18. They found
that CAP18 intercalates into lipid matrices composed of LPS
from sensitive strains, less than into those made of LPS from a
resistant strain (Proteus mirabilis strain R45) or negatively
charged phospholipids, but not into those composed of neutral
phosphatidylcholine [30]. Other studies point to the tight
packing of the lipid acyl chains of LPS bilayers [25,27], to the
variations in the chemical structure of LPS, e.g., in the com-
position of the sugar head group [31], and to the highly charged
O-specific sugar side chains [32], as the causes for the bacteria
resistance towards antibacterial peptides. Recent studies in our
laboratory have shown that in order to promote bacterial death
peptides have to traverse the outer membrane and reach the
inner phospholipid layer to bind and disintegrate it. However,
when peptides' aggregation is triggered upon binding to LPS,
they tend to form bulky compounds that prevent them from
crossing the outer membrane and reaching their final target (Fig.
1) [25]. In this study two model peptides were investigated, an
all-L amino acids peptide and its D,L counterpart. Antimicrobial
assay showed that the D,L peptide is more active against Gram-
negative bacteria compared to its all-L counterpart (the MICs
were 5 and >100 μM against E. coli for the D,L and the all-L
peptides, respectively). Diffusion potential assays with both
intact bacteria and bacterial spheroplasts showed that the
activity of both the all L-amino acid peptide and its diastereomer
was equal when tested, for example against E. coli spheroplasts
[25]. In contrast, the diastereomer was much more active (up to
ten-fold) than the all L-peptide when tested on intact E. coli.
This is in agreement with the notion that LPS is the cause for the
differences in the antibacterial activity of the two peptides.
ATR-FTIR measurements revealed that the all-L peptide tends
to aggregate on LPS film (75% α-helix and 25% aggregated β-
strands), while the D,L peptide has a distorted structure. The
different structure correlated with the peptides effect on the
phosphate headgroups of the LPS. While the D,L peptide
reduced the signal of both headgroups, the all-L peptide affects
only the outer phosphate, indicating that it cannot pass the LPS
barrier (Fig. 2). Note that in a different study a similar effect was
observed in experiments done with rabbit CAP18 in LPS
suspension [30]. Besides pointing to the molecular mechanism
of LPS protection, this study suggests a potential strategy of
reducing the aggregation of antimicrobial peptides to overcome
the LPS barrier, which will help in the designing of novel
antibacterial peptides as future therapeutics.
3. Modifications of LPS are induced upon bacteria
recognition of antibacterial peptides
Pathogenic bacteria are capable of changing the expression
of virulence genes essential to survival and replication, by
Fig. 1. (A) Schematic structure of Gram-negative outer membrane. Kdo, 3-deoxy-D-manno-oct-2-ulopyranosonic acid; P, phosphate. (B) Schematic representation of
mode of binding of the K5L7 peptide with LPS. The peptide binds first predominantly by electrostatic interactions to the LPS, self-associates, and cannot traverse into
the lipid core. (C) Schematic representation of the possible mechanism of membrane lysis by the 4D-K5L7 peptide. The peptide binds first predominantly by
electrostatic interactions to the LPS and stays as monomers. The peptide then accumulates on the surface of the lipidic core until a threshold concentration is reached,
followed by LPS micellization [25].
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their host [33,34]. In the case of some pathogenic bacteria, such
as Salmonella typhimurium and Salmonella typhi, some of the
virulence genes are controlled by the two component regulatory
system, PhoP/PhoQ [35]. In this two component system the
sensor protein, PhoQ, phosporylates and activates PhoP, a
transcriptional regulatory protein, which in turn activates or
represses over 40 different genes [36]. The activation of these
genes was found to be essential to the survival of these patho-
genic bacteria within the host macrophages [37]. The virulence
of Salmonella was related to its resistance to antimicrobial
peptides [38]. In their study Groisman et al. studied the
virulence of different salmonella mutants, which fell into dif-ferent phenotypic classes with respect to their susceptibility to
rabbit defensin NP-1, frog magainin 2, pig cecropin P1, and the
insect venom-derived peptides mastoparan and melittin. They
were able to characterize the mutations to defective LPS and to
PhoP [38]. Other genes related to the salmonella antimicrobial
resistance that are activated by PhoP/PhoQ were characterized
later [39,40]. Guo et al. [41] found that lipid A acylation
mediated by PhoP/PhoQ induced gene, PagP, is important to
inducible antimicrobial peptides resistance. PagP encodes an
unusual enzyme of lipid A biosynthesis localized in the outer
membrane, which is the first example of an outer membrane
enzyme involved in lipid A biosynthesis [42]. Pag L is another
gene that is activated by PhoP/PhoQ, which encodes a lipase
Fig. 2. FTIR spectra deconvolution of the fully deuterated amide I band (1600–
1700 cm–1) of K5L7 (A) (K L L L K L K L K L L K-NH2), and its diastereomer
4D-K5L7 (B) (K L L L K L K L K L L K-NH2, bold and underlined amino acids
are in the D-form) peptides in LPS multibilayers. Second derivatives were
calculated to identify the positions of the component bands in the spectra. The
component peaks are the result of curve-fitting using a Gaussian line shape. The
sums of the fitted components superimpose on the experimental amide I region
spectra. Continuous lines represent the experimental FTIR spectra; broken lines
represent the fitted components. (C) The influence of the different peptides on
the head groups of LPS. IR absorbance spectra are shown for LPS multibilayers
in the range of the asymmetric stretching vibration of the negatively charged
phosphates νas(PO2
−) for the different peptides. I designates the IR band of the
peptide; II and III are the vibrational bands of LPS corresponding to different
hydration of the phosphates. A 60:1 lipid/peptide molar ratio was used [25].
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branes of Salmonella typhimurium [43]. Recently, the molecular
mechanism by which the bacteria sense host defense peptides
through the PhoP/PhoQ two component system was discovered
[44]. In the model suggested, the sensor domain, PhoQ, senses
the presence of antimicrobial peptides when these peptides
displace divalent cations from its metal binding sites [44]. This
leads to activation of the transcription factor, PhoP, which
activates a series of genes that are related to the resistance of the
bacteria to the host antimicrobial peptides. Several native
antimicrobial peptides were found to induce bacteria resistance,
among them human LL-37, polymixin B, magainin II, and
others [40,44,45]. This mechanism of bacterial resistance
emphasizes the need to modify antimicrobial peptides so they
will be able to overcome these modifications, or better, will not
activate this bacterial regulatory system [46].
4. Bacterial cell wall/outer membrane components activate
the innate immune system
The host immune system evolved to recognize conserved
bacterial molecular patterns, among them bacterial cell wall/
outer membrane components (LPS in Gram-negative bacteria
and lipotheichoic acid (LTA) in Gram positive bacteria) as
signals of bacterial infection [47]. Upon their release from
bacteria as a result of cell division, death, or in particular,
antibiotic treatment against bacterial infection, these compo-
nents are recognized as pathogen associated molecular pattern
(PAMPs) by the pattern recognition receptors (PRRs), among
them toll like receptors (TLRs) [3,48–50]. These receptors are
expressed on innate immune cells, mainly by mononuclear
phagocytes (monocytes and macrophages) resulting in their
activation that is characterized by increased phagocytic activity,
secretion of pro-inflammatory cytokines such as tumor necrosis
factor-alpha (TNF-α), interleukin 6 (IL-6), interferon-β, and
induction of other pro-inflammatory proteins synthesis, such as
inducible NO synthase (iNOS) [51–55].
Activation of the immune system by PAMPs is beneficial,
and helps the organism to recruit all its resources in order to fight
the invading pathogen in the right time and place. However, in
several cases prolonged and uncontrolled activation causes
systemic and prolonged response of the immune system. This
systemic response is characterized by high pro-inflammatory
cytokine concentrations in the blood, especially TNF-α [56,57].
TNF-α is the major mediator causing the pathological effects
characterizing endotoxic shock. Among them, endothelial
damage, loss of vascular tone, coagulopathy and multiple-
system organ failure often resulting in death [57,58].
Two major approaches were discussed regarding the
mechanism of macrophage stimulation by LPS, and in order to
try to overcome the unbalanced activation of these cells in the
case of sepsis. The first one utilized LPS receptor antagonists
that included anti-CD14 antibodies, anti-LBP antibodies, as well
as lipid A analogs, all of which bound and blocked essential
components participating in the signaling mechanism [59,60].
The second approach utilized LPS blockers such as anti-lipid A
antibodies and modified liposomes, both of which bound to LPS
Table 1
LPS neutralizing peptides, their source and suggested mode of action
Peptide Source Suggested mode
of action
Reference
CAP18 Rabbit Direct binding to LPS [98]
CEMA CEME Synthetic-hybrid
of silk moth
cecropin and bee
melittin
Direct binding to LPS [90,91]
CAP37 Human
neutrophils
Direct binding to LPS [99]
Polymyxin B Bacillus
polymyxa
Direct binding to LPS [100,101]
LL-37 Human CAP18 Direct binding to LPS,
compete with
LPS on its
receptor-CD14,
disaggregate
LPS oligomers
[87,93,94,96]
Buforin II Bufo bufo
gargarizans
Direct binding to LPS [102]
Indolicidin Cytoplasmic
granules of
bovine
neutrophils
Direct binding to LPS [102]
KFFKFFKFF Synthetic Direct binding to LPS [102]
NK-2 Mammalian
NK-lysin
Direct binding to LPS,
influence the
supramolecular
structure of lipid
A aggregates
[28]
LF11 Lactoferricin-
derived peptide
Direct binding to LPS,
influence the
supramolecular
structure of lipid
A aggregates
[95]
RLYLRIGRR-NH2 Beetle
Allomyrina
dichotoma
defensin
Direct binding to LPS [103,104]
All-L K6L9 Synthetic Direct binding to LPS,
disaggregate LPS
oligomers
[96]
D, L K6L9 Synthetic Direct binding to LPS,
disaggregate
LPS oligomers
[96]
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However, although these studies help us to understand the steps
involved in LPS neutralization, the approaches used in the above
mentioned works did not deal with the bacteria from which LPS
originates, pointing to the need for a new agent that can
neutralize LPS as well as eliminate its source.
5. Host defense peptides as immune system modulators
In the past yearsmore evidence has accumulated regarding the
ability of antimicrobial peptides to modulate the innate immune
system as their additional role in host defense [13,21,64,65] (for
detailed review see [66]). Some antimicrobial peptides have
demonstrated a range of pro-inflammatory functions related with
immunity of the host. For example, LL-37 and some defensins
were reported to have immunomodulatory activities that are part
of the development of local inflammation. It was established that
they were able to promote wound healing, where they served as
common growth factors promoting epithelial cells proliferation
[67–70]. The peptides stimulated chemokines and cytokines
expression (such as, interleukin-8 (IL-8), macrophage chemo-
taxis factor-1 (MCF-1), and others) by macrophages and
epithelial cells [71–73]. They and other peptides promote
immune cell (mast cells, macrophages, neutrophils and T cell
lymphocytes) chemotaxis, probably via the formyl peptide
receptor-like 1 (FPRL1) [74–78]. They were also found to
promote angiogenesis [79,80]. It seems that the protective
mechanisms of some host defense peptides initiate subtle
changes in host cells by a complex cascade which leads to an
overall defense response.
In contrast to these activities, antimicrobial peptides have the
ability to reduce the pro-inflammatory response by directly
interacting with bacterial membrane and cell wall components
PAMPs, making them unavailable to pattern recognition
receptors, therefore preventing phagocyte activation and pro-
inflammatory cytokines secretion [64,65]. Rifkind and Palmer
were the first to report that three cationic cyclic polypeptide
antibiotics, polymyxin-B sulfate, colistin sulfate, and tyrocidine
hydrochloride, were shown to neutralize endotoxin lethality in
chick embryos [81]. Ooi et al. [82] reported on the endotoxin
neutralizing activity of the N-terminal fragment of bactericidal/
permeability-increasing protein (BPI) of polymorphonuclear
leukocytes. They found that the principal determinants for LPS
recognition and neutralization, like those for antibacterial action,
reside in the N-terminal half of the BPI molecule, but sites within
the C-terminal half can also contribute to BPI-LPS interaction
once LPS is detached from the bacterial envelope. Other LPS
binding proteins, such as Limulus anti-lipopolysaccharide factor
(LALF) from amoebocyte [83] and LPS binding protein (LBP)
[84,85] were also found to have anti endotoxic activity. A few
years later studies were reported on the LPS neutralizing activity
of native host defense antimicrobial peptides. The first peptide
that was reported is leukocyte protein rabbit CAP18 (cationic
antimicrobial protein, 18 kDa) [86–88]. Scott et al. found that not
only mammalian antimicrobial peptides are capable in neutraliz-
ing LPS, but also synthetic α-helical cationic peptides related to
bee melittin and silk moth cecropin are capable in preventingcytokine secretion by macrophages stimulated with LPS or with
lipoteichoic acid (LTA) [89–91]. Overall, out of the thousands
known antimicrobial peptides only a few native and synthetic
antimicrobial peptides were investigated for their ability to
neutralize LPS (see list in Table 1) (for more detailed reviews
about anti-endotoxin peptides see [14,92].
By further investigating the antimicrobial peptides–LPS
interaction, two mechanisms were suggested: (i) the peptides
directly bind to LPS, making it unavailable to LBP and therefore
unable to transfer it to its primary receptor, CD14 [90]. (ii) The
peptide antagonizes the receptor by binding directly to CD14
and prevents LPS to bind to the receptor. This mechanism was
demonstrated only in the case of the human cathelicidin family
peptide, LL-37 [90,93,94]. Recently this peptide was found to
modulate the inflammatory response to LPS/endotoxin and other
agonists of TLR by a complex mechanism that involves multiple
Fig. 3. A cartoon outlining the major events in induction of sepsis by bacteria and the points at which cationic peptides are proposed to intervene. Antibiotics can
stimulate the release of endotoxin (LPS) which binds to LPS-binding protein (LBP) present in the blood, and transfers it to CD14 receptor on the surface of immune
cells. This complex initiates intracellular signaling reactions, which mediate the production of inflammatory cytokines [15]. AMPs inhibit this event by several
mechanisms: (A) by direct binding to LPS, making it unavailable to LBP; (B) by competing with LPS for binding to the TLR signaling complex; (C) by inhibiting
NFκB translocation into the nucleus [73]; (D) by altering inflammatory genes expression through direct triggering of the MAPK pathways; and (E) by direct killing of
microbes either via disruption of their membranes or by reacting with internal molecules.
Fig. 4. The relationship between peptide concentration and the LPS-FITC aggregation state. LPS-FITC (0.5 μg/ml) was treated with increasing concentrations of
peptides. The change in FITC emission after each treatment was monitored until emission reached equilibrium. The increase in emission reflected the change in the
LPS-FITC aggregational state. FITC increases its emission when the distance between its monomers increases due to self-quenching. Experiments were repeated three
times with 5% variations. Peptides designations; Amphipathic-L (L K L L K K L L K K L L K L L-NH2), Amphipathic-D (L K L L K K L L K K L L K L L-NH2),
bold and underlined amino acids are in the D-form [96].
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protect the host against microbial pathogens by multifaceted
mechanism with several points of intervention. A model
outlining the major events in induction of sepsis by bacteria
and the points at which cationic peptides are proposed to
intervene is presented in Fig. 3.
The interactions between LPS and NK-2, a membrane-acting
antimicrobial peptide derived from the cationic core region of
porcine NK-lysin were investigated by Andra et al. [28]. They
suggested that hydrophobic peptide–LPS interaction is necessary
for efficient neutralization of the biological activity of LPS and
that the long carbohydrate chains, besides their function as a
barrier for hydrophobic drugs, also serve as a trap for polycationic
substances [28]. In another study, the interaction of lactoferricin-
derivedpeptideLF11and itsN-terminally acylated analoguewith
LPS were investigated [95]. Both peptides convert the mixed
unilamellar/non-lamellar aggregate structure of lipid A, the
‘endotoxic principle’ of LPS, into a multilamellar one, but
alkyl derivative peptide lauryl-LF11 shows a much stronger
inhibition of the LPS-induced cytokine induction. This study
suggests that neutralization of the LPS surface charges is a
requirement, but not sufficient, for effective LPS detoxification
by cationic peptides. A significant increase in inhibitory activity
would be observed if a hydrophobic interaction occurs, resulting
in changes in LPS aggregative state [95].
Recently, we explored the ability of LL-37, magainin, 15-mer
all-L synthetic peptide (amphipathic-L) and its D,L counterpart
(amphipathic-D) to detoxify LPS. We found that strong binding
of a peptide to LPS aggregates accompanied by aggregate
dissociation prevents LPS from binding to the carrier protein
lipopolysaccharide-binding protein, or alternatively to its
receptor, and hence inhibits cytokine secretion by macrophages
[96]. Using bothRT-PCR andTNF-αELISAwe showed that LL-
37, amphipathic-L, amphipathic-D, but not magainin can inhibit
the induction and secretion of pro-inflammatory cytokines by
macrophages. Binding experiment showed that all peptides have
similar high affinity towards LPS. All the peptides could bind
LPS when it is already bound to macrophages, but only LL-37
partly displaces it, indicting that LL-37 competes with LPS on its
receptor. We utilized FITC properties in order to examine the
effect of the peptides on LPS-FITC aggregates. Dissociation of
the aggregates results in an increase in the fluorescence of FITC
because of dequenching [97], thus enabling us to follow the
changes in LPS aggregative state. This assay showed that the
peptides ability to detoxify LPS correlate with their ability to
disaggregate LPS (Fig. 4). This study further suggested that there
is no correlation between the peptides' antimicrobial activity and
its ability to neutralize LPS, indicating that different properties
are needed for each activity. Furthermore, this study showed that
a defined secondary structure is not essential for LPS neutralizing
activity: the synthetic D,L amino acid peptide was still active
similarly to its all-L counterpart [96].
6. Conclusions
In summary, the biophysical properties and the mode of
action of AMPs with LPS determine their biological function,the susceptibility of bacteria to them, the ability of LPS to
activate the immune system, as well as the potential of AMPs to
interfere with this activation and to neutralize LPS-induced
endotoxic shock. From a therapeutic point of view, although
antimicrobial peptides were found to be potential candidates for
treatment against endotoxic shock and bacterial infection both
in vitro and in vivo, still no peptide is available for clinical use
mainly because of toxicity and stability problems. This should
encourage further investigation of the peptides properties and
their modes of action. Better understanding of the peptides
characters involved in antibacterial activity, LPS neutralization,
toxicity and stability should help us to develop improved
antimicrobial peptides with desirable properties.
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